For instance, studies on glioma, NSCLC, and melanoma have shown that rising sPD-L1 levels during therapy often precede radiological progression and poor outcomes, whereas stable or decreasing levels are associated with favorable responses [80,81,82]. Here, SPDL1 is linked to melanoma.